Clinical Trials | November 13, 2025
Philogen updates on Fibromun clinical study developments
FIBROSARC did not meet its primary PFS endpoint in the final analysi
FIBROSARC did not meet its primary PFS endpoint in the final analysi
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Poviztra is a second brand of Wegovy
The said inspection concluded with Zero Form 483 observation
Subscribe To Our Newsletter & Stay Updated
